Deepika Pakianathan, Director at Karyopharm Therapeutics Inc. (KPTI), bought 114,419 shares at $26.19 ($3.0M) on 2014-05-21, disclosed to the SEC on 2014-05-23.
Open-market purchase of $3.0M KPTI by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.19 | 896 | $23K | 0.8% |
| 2 | $26.19 | 91,754 | $2.4M | 80.2% |
| 3 | $26.09 | 193 | $5K | 0.2% |
| 4 | $26.09 | 19,807 | $517K | 17.3% |
| 5 | $26.45 | 17 | $450 | 0.0% |
| 6 | $26.45 | 1,752 |
| $46K |
| 1.5% |
| Total | $26.18 avg | 114,419 | $3.0M | 100% |
| Filing → |
| KPTI | SELL | 2024-06-04 | $1.4M | — | Filing → |
| CALA | SELL | 2023-01-31 | $47K | — | Filing → |
| KPTI | SELL | 2022-06-10 | $6.8M | — | Filing → |